Inhaled vasodilator therapy in acute lung injury: first, do NO harm?
The acute respiratory distress syndrome in adults (ARDS) is defined by refractory hypoxaemia in the presence of radiographic evidence of bilateral pulmonary infiltrates.' The full-blown syndrome and lesser degrees of acute lung injury (ALI) are characterised by the presence of high permeability alveolar oedema, a loss of hypoxic pulmonary vasoconstriction (HPV) leading to a marked increase in ventilation-perfusion mismatch, and increased pulmonary vascular resistance (PVR). Adverse changes in ventilationperfusion account almost wholly for the hypoxaemia that characterises ALI/ARDS' and the rise in PVR is commonly associated with clinically significant right ventricular dysfunction3 leading, in turn, to preload limitation, septal shift, and impaired left ventricular performance.45 The detrimental effects on cardiac performance almost certainly contribute to morbidity and, in some patients, mortality. Given that the discovery of a pharmacologically distinct receptor population in the pulmonary circulation has proved elusive, investigators have attempted to manipulate PVR in patients with lung injury using agents with particular pharmacological or physical properties. For example, a rapidly metabolised drug with a very short half life administered intravenously may no longer possess biological activity by the time it reaches the systemic circulation. Thus, adenosine has been shown to have a vasodilator effect specific to the pulmonary circulation when infused into patients with primary pulmonary hypertension," but in biventricular failure it induces significant increases in pulmonary artery occlusion pressure,12 suggesting a negative effect on ventricular diastolic performance which would clearly be unhelpful in patients with cardiac function compromised by ALI/ARDS.
By contrast, the use of inhaled vasodilators is theoretically doubly attractive. Any lack of pharmacological specificity for the pulmonary circulation becomes less relevant, provided that agents are inactivated by the time the systemic circulation is reached. If the action of such drugs is confined to the area of deposition, then blood will be recruited to lung units to which the inspired gas has access, thereby reducing shunt fraction and PVR. To date, most laboratory and clinical experience has been gained in ALI/ ARDS using inhaled nitric oxide (NO).'3-'" An increasing body of clinical evidence suggests that the theoretical advantages outlined above are borne out in practice, with beneficial reductions in PVR and improvements in gas exchange.
In 1993 Rossaint et al published the results of a small study of nine patients with ARDS."' Nitric oxide, 18 ppm, was administered by inhalation for 40 minutes, producing a significant reduction in the mean pulmonary artery pressure, and an increase in the Pao2/Fio2 ratio. The mean shunt fraction was reduced significantly from 36% to 31%. Seven patients were subsequently treated with inhaled NO for 3-53 days during which time the investigators were able to reduce the inspired oxygen concentration by 15%. They did not observe any adverse systemic haemodynamic consequences. By contrast, infusion of intravenous prostacyclin caused an increase in shunt and a reduction in systemic arterial pressures. Similar findings have been reported in similar patients using inhaled NO at considerably lower concentrations. '6 Furthermore, NO at 2 ppm completely reversed the increase in PVR associated with the hypercapnia resulting from low frequency ventilation, a technique commonly employed in the management of ARDS. Moreover, this modest dose of NO produced beneficial effects on gas exchange.
However, not all patients seem to benefit from NO inhalation and no firm data have emerged to suggest that it causes a significant reduction in ARDS-associated mortality. This may not be altogether surprising since such patients tend to die from the associated underlying disease or the twin complications of sepsis and multiple organ failure. Survival may therefore be an insensitive end point, and the achievement of physiological goals or reduced morbidity/ventilator time may represent more appropriate targets for controlled trials. '8 Nevertheless, the encouranging preliminary results reported with administration of NO by inhalation to patients with ALI/ARDS have led to widespread uncontrolled use of this potentially exciting therapy. The logistics of its safe administration are complex. NO reacts with oxygen to form nitrogen dioxide which dissolves to form toxic nitrous acid. The reaction rate is dependent upon the available oxygen concentration, so the time it spends in combination with high concentrations of oxygen must be kept to a minimum. There are a number of ventilator circuits which have been designed specifically to overcome this problem, and simple nitrogen dioxide fuel cell analysers are available which should also contribute to patient monitoring and therefore safety.
However, the drug remains unlicensed and there is no standardised protocol of administration nor formalised means of monitoring systems of administration. Furthermore, the assumption that the evanescence of NO equates to a benign local action is almost certainly an oversimplification. NO reacts rapidly with haemoglobin '9 and is therefore carried from the lung into the systemic circulation, albeit in modified form. Knowledge of the physiology ofNO derivatives in animal models is increasing rapidly and providing contradictory results.
The most frequently quoted toxicology studies describe experiments in which non-diseased animals are exposed to inhaled NO. Exposure of rats to 1000 ppm NO for 30 minutes,20 exposure of rabbits to 43 ppm for six days,21
and long term studies (six months) in mice22 have not demonstrated histological, ultrastructural, or gravimetric evidence of pulmonary toxicity. Unfortunately, such investigations provide no guide to possible toxic effects in diseased lungs with ongoing inflammatory processes and cannot therefore be regarded as totally reassuring. Furthermore, rabbits inhaling 30 ppm NO for 15 minutes displayed significantly prolonged bleeding times, and 300 ppm significantly reduced systemic arterial pressures.23
The availability ofNO synthase (NOS) antagonists, such as N0-monomethyl-L-arginine (L-NMMA), has enabled scientists to investigate the role of endogenous NO in a variety of physiological and pathological systems. In ALI/ ARDS, macrophages and activated neutrophils are recruited to the lung2425 where they release reactive oxygen species (ROS).2627 Hydrogen peroxide and nitrotyrosine, markers of ROS activity, have been detected in breath condensate28 and lung tissue,29 respectively, from patients with ARDS. Furthermore, endotoxaemia stimulates the expression of the messenger RNA for the calcium-independent, inducible isoform of NOS (iNOS) in rats. 30 In pathological states there may therefore be a secondary increase in NO generation. There is increasing evidence to suggest that NO may be an effective scavenger ofROS3' and may inhibit xanthine oxidase,32 an enzyme which produces superoxide. In this sense NO may be cytoprotective.
By contrast, under hypoxic conditions NO reacts with superoxide to form peroxynitrite33 which is profoundly cytotoxic. This reaction occurs three times faster than the scavenging of superoxide by the antioxidant superoxide dismutase. The exact nature of peroxynitrite toxicity is emerging slowly, but it may be responsible for surfactant damage and be directly injurious to proteins,34 producing nitrotyrosine residues. These have been detected in both animal models and in lung tissue from patients with ARDS. 20 ppm, a concentration several orders of magnitude greater than the estimated concentration of endogenous NO in alveolar gas, peroxynitrite levels may increase and fuel oxidant-mediated inflammation.
Infants with severe congenital heart disease,39 persistent fetal circulation,40 and diaphragmatic hernia4' often suffer considerable morbidity and mortality due to severe pulmonary hypertension. For these patients the issues may be different: they may die because of cardiac impairment consequent upon elevated PVR and the chance to control the circulation with NO may considerably increase their changes of survival. An enlarging literature supports this indication for inhaled NO therapy where different riskbenefit equations may apply.
Nitric oxide improves gas exchange and reduces PVR in some patients with ARDS, an attractive option in a condition desperately short of effective therapeutic interventions. For some this may mean the difference between survival and non-survival, and rapid growth in the (largely) unmonitored use of inhaled NO is understandable. However, the potential for harmful side effects may emerge increasingly as our understanding of the biology of NO increases. In this sense the principle of primum non nocere should not be forgotten. The information to allow a reasoned risk-benefit analysis of NO therapy may be extremely hard to obtain, but hopefully will be forthcoming.
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